Compare AbCellera Biologics Inc (ABCL) vs Corning Incorporated (GLW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Corning Incorporated — how do they compare? AbCellera Biologics Inc trades at $7.13 (market cap $2.35B), while Corning Incorporated trades at $185.04 (market cap $159.55B). The key difference: Corning Incorporated is far larger — about 67.9× AbCellera Biologics Inc's market cap, and Corning Incorporated pays a 0.6% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | GLW | |
|---|---|---|
Market Cap | $2.35B | $159.55B |
Sector | Health | Technology |
52-Week High | $8.12 | $255.79 |
52-Week Low | $2.78 | $51.60 |
Enterprise Value | $1.99B | $167.71B |
Dividend Yield | — | 0.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Corning Inc. (GLW) trades at $185.38, down 5.75% amid recent AI-related stock volatility, yet maintains strong fundamentals with Q1 2026 EPS beating estimates at $0.70. Revenue grew to $15.63B in 2025, with net income margin improving to 10.21%. Technical indicators show a bullish overall signal despite near-term bearish moving averages, with key support at $185. Recent news highlights AI-driven fiber demand as a growth catalyst, though competition and China exposure pose risks.
The outlook remains positive with a consensus price target of $206.60, implying 11.4% upside, supported by 54% analyst buy ratings. Risks include high valuation multiples (P/E 93.65) and dependency on AI infrastructure spending cycles. Institutional sentiment is bullish, but investors should monitor earnings consistency and macroeconomic pressures on tech stocks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Corning Incorporated
Corning Inc is a leader in materials science, specializing in the production of glass, ceramics and optical fiber. The firm supplies its products for a wide range of applications, from flat-panel displays in televisions to gasoline particulate filters in automobiles to optical fiber for broadband access, with a leading share in many of its end markets.
Read more on GLW →
